No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DAVE Dave Inc
- 30.500
- +0.510+1.70%
Close Jul 3 13:00 ET
377.78MMarket Cap-108928P/E (TTM)
31.380High29.915Low267.10KVolume30.200Open29.990Pre Close8.25MTurnover3.55%Turnover RatioLossP/E (Static)12.39MShares63.50052wk High2.97P/B229.55MFloat Cap4.72052wk Low--Dividend TTM7.53MShs Float491.069Historical High--Div YieldTTM4.89%Amplitude4.466Historical Low30.877Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
A Fintech Collapse Is Rippling Through a Small Corner of the Banking World
Seaport Global Maintains Dave Inc(DAVE.US) With Buy Rating, Maintains Target Price $58
Seaport Global analyst Jeff Cantwell maintains $Dave Inc(DAVE.US)$ with a buy rating, and maintains the target price at $58.According to TipRanks data, the analyst has a success rate of 56.3% and a to
Dave Price Target Maintained With a $60.00/Share by B. Riley Securities
Dave Price Target Maintained With a $60.00/Share by B. Riley Securities
Dave Is Maintained at Buy by B. Riley Securities
Dave Is Maintained at Buy by B. Riley Securities
Critical Insights From Dave Analyst Ratings: What You Need To Know
In the latest quarter, 9 analysts provided ratings for Dave (NASDAQ:DAVE), showcasing a mix of bullish and bearish perspectives.The following table summarizes their recent ratings, shedding light on t
JMP Securities Reiterates Market Outperform on Dave, Maintains $75 Price Target
JMP Securities analyst Devin Ryan reiterates Dave (NASDAQ:DAVE) with a Market Outperform and maintains $75 price target.
Comments
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings(SWVL.US$718.40%
![]()
$Root Inc(ROOT.US$564.60%
![]()
$Elevation Oncology(ELEV.US$561.08%
![]()
$JanOne(JAN.US$554.05%
![]()
$GeneDx Holdings(WGS.US$520.71%
![]()
$Corbus Pharmaceuticals(CRBP.US$513.25%
![]()
$AGBA Group(AGBA.US$482.90%
![]()
$Janux Therapeutics(JANX.US$431.22%
![]()
$Dave Inc(DAVE.US$4...
A quick recap for the month ending April 30, 2024.
4
1
Despite strong revenue growth, Dave's low P/S ratio may indicate investor belief of underperformance in the broader industry. Shareholders may think recent performance has peaked, leading to lower selling prices. The low P/S ratio could signal price risks if medium-term revenue trends persist, but investors anticipate future revenue volatility.
Dave Inc.'s CEO, Jason Wilk, sees the recent transaction as a major advancement for the company, offering a unique chance to increase shareholder value. He remains confident in the company's ability to meet its growth and profitability goals in the future quarters.
$Dave Inc(DAVE.US$ Something not right… it is now at 9.05
Despite strong revenue growth that outpaces the industry, Dave's P/S ratio is surprisingly low. This could suggest underlying risks to the company's future performance as investors may not be convinced the company can maintain its recent growth rates.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Mars MoooOP :